| A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue) (NCT04514107) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-09-09 |
| SARS-COV2 Pandemic Serosurvey and Blood Sampling (NCT04334954) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-08-26 |
| ACTIV-2: A Study for Outpatients With COVID-19 (NCT04518410) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-08-19 |
| LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (NCT05780268) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-08-05 |
| Adaptive COVID-19 Treatment Trial 3 (ACTT-3) (NCT04492475) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-08-05 |
| ACTIV-3: Therapeutics for Inpatients With COVID-19 (NCT04501978) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-08-04 |
| Malaria Prevalence Around Maferinyah, Guinea (NCT04105855) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-07-13 |
| Surveillance of Individuals Following SARS-CoV-2 Infection (NCT04383444) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-07-07 |
| A Longitudinal Study of COVID-19 Sequelae and Immunity (NCT04411147) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-06-17 |
| Collection of Anti-SARS-CoV-2 Immune Plasma (NCT04344977) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-06-01 |
| COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (NCT04401436) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-05-22 |
| Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 (NCT04358068) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-05-13 |
| Adaptive COVID-19 Treatment Trial 2 (ACTT-2) (NCT04401579) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-05-08 |
| COVID-19: Human Epidemiology and Response to SARS-CoV-2 (NCT04375761) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-05-01 |
| Immunophenotyping Assessment in a COVID-19 Cohort (NCT04378777) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-05-01 |
| Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) (NCT04283461) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-03-16 |
| Glutamine Supplementation in People With Immune Dysregulation (NCT04019769) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-03-12 |
| Belimumab With Rituximab for Primary Membranous Nephropathy (NCT03949855) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-03-06 |
| StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis (NCT03882177) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-02-21 |
| Adaptive COVID-19 Treatment Trial (ACTT) (NCT04280705) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-02-21 |
| Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males (NCT04692077) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-02-19 |
| Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe) (NCT04097561) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-01-13 |
| Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults (NCT04177355) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-01-13 |
| Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy (NCT03965923) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-01-09 |
| Trial to Evaluate CIS43LS in Healthy Adults (NCT04206332) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-01-07 |
| Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 (NCT03739996) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-12-31 |
| Paradoxical Tuberculosis Reactions in Patients Without HIV Infection (NCT04052022) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-12-20 |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (NCT04047628) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-12-19 |
| Treg Modulation With CD28 and IL-6 Receptor Antagonists (NCT04066114) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-12-11 |
| Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally (NCT04047420) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-12-11 |
| Safety and Pharmacokinetics of Rezafungin (NCT04117607) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-12-04 |
| Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (NCT03910452) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-10-28 |
| H1N1v Virus Challenge Study in Healthy Subjects (NCT04044352) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-10-22 |
| Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine (NCT04025580) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-10-02 |
| Plasmodium and Other Parasites in Pregnant Women and Children Around Margibi and Montserrado Counties, Liberia (NCT03719599) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-10-01 |
| Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants (NCT03937817) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-09-25 |
| Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects (NCT04019444) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-09-19 |
| Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa (NCT02644525) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-09-16 |
| Suppression Of Bacterial Vaginosis (BV) [SUBVert] (NCT03930745) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-09-09 |
| Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants (NCT03934541) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-08-26 |
| PREVAIL VIII: A CoHOrt Clinical, Viral, and ImmuNOlogic Monitoring Study of People Living With Retroviral Infection in Liberia (HONOR) (NCT03733093) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-08-22 |
| Asymptomatic Congenital CMV Treatment (NCT03301415) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-08-21 |
| Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART (NCT03787095) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-08-13 |
| Febrile Disease Landscape in Cambodia Via Metagenomic Pathogen Sequencing (NCT04034264) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-07-23 |
| Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (NCT03881696) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-07-22 |
| Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies (NCT03610802) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-07-22 |
| Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants (NCT03928821) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-07-17 |
| A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam (NCT03978091) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-07-09 |
| Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine (NCT04009824) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-07-08 |
| Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali (NCT03989102) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-07-03 |
| Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults (NCT04041570) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-07-02 |
| Intravenous Fosfomycin Pharmacokinetics Study (NCT03910673) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-06-27 |
| Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age (NCT03916185) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-06-20 |
| Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis (NCT03770273) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-06-19 |
| Dual bNAb Treatment in Children (NCT03707977) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-06-17 |
| Flublok or Fluzone With Advax-CpG55.2 or AF03 (NCT03945825) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-06-10 |
| Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (NCT03568383) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-06-03 |
| Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa... (NCT03952650) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-05-23 |
| A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells (NCT03856996) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-05-23 |
| Pharmacokinetics and Safety of SAR441236 (NCT03705169) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-05-20 |
| Dried Blood Spot Testing of CMV Detection in HCT Recipients (NCT03910478) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-05-03 |
| Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route (NCT03845231) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-04-29 |
| Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali (NCT03917654) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-04-24 |
| Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis (NCT03835767) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-04-19 |
| Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers (NCT03878121) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-04-17 |
| Safety Study of Hepatitis E Vaccine (HEV239) (NCT03827395) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-04-12 |
| Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions (NCT03831945) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-04-04 |
| More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (NCT03497676) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-04-03 |
| VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults (NCT03879603) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-04-02 |
| Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults (NCT03814720) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-04-01 |
| Liver Transplantation With Tregs at MGH (NCT03577431) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-03-29 |
| The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE (NCT03635788) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-03-28 |
| HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study (NCT03560258) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-03-26 |
| A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area (NCT03548064) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-03-10 |
| Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults (NCT03783130) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-03-07 |
| Clinical Study of a Diagnostic Device for NG, TV and CT in Women (NCT03852316) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-02-27 |
| Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device (NCT03682107) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-02-19 |
| Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIV (NCT03141060) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-02-18 |
| An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC) (NCT03908632) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-02-14 |
| Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia (NCT03519464) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-02-04 |
| Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants (NCT03589768) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-01-24 |
| Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants (NCT03735849) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-01-18 |
| Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population (NCT03593655) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-01-14 |
| Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD) (NCT03548051) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-01-11 |
| Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals (NCT03816878) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-01-08 |
| Retrospective Chart Review of Candida Fungemia (NCT03827330) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-01-03 |
| Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir (NCT03670355) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-01-02 |
| Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults (NCT03505060) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-01-01 |
| rCSP/AP10-602 [GLA-LSQ] Vaccine Trial (NCT03589794) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-12-21 |
| Tocilizumab in Cardiac Transplantation (NCT03644667) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-12-20 |
| Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus (NCT03618056) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-12-19 |
| 2017 A/H7N9 IIV Revaccination (NCT03738241) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-12-18 |
| Vaginal Microbiome Exposure and Immune Responses in C-section Infants (NCT03567707) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-11-28 |
| Investigational Therapeutics for the Treatment of People With Ebola Virus Disease (NCT03719586) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-11-21 |
| A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z) (NCT03583606) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-11-12 |
| Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS) (NCT03697993) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-11-07 |
| Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza (NCT03682120) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-11-02 |
| Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection (NCT03637660) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-10-31 |
| Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults (NCT03541499) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-10-23 |
| NNITS-Nitazoxanide for Norovirus in Transplant Patients Study (NCT03395405) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-10-15 |